Aethlon Medical(AEMD)

Focus: Aethlon Medical is a public biotech focused on dialysis filtration technology for nephrology, specifically targeting end-stage renal disease treatment. The company operates at pre-revenue scale with minimal commercial traction and faces significant cash burn.

Nephrology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Aethlon Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Aethlon Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$574K

Pipeline & Clinical Trials

Hemopurifier

End Stage Renal Disease

N/A

Clinical Trials (3)

NCT02215902Safety Study of the Aethlon Hemopurifier

N/A

Help build intelligence for Aethlon Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage medical device innovation in a high-need therapeutic area (nephrology/dialysis) with potential for transformative impact
Public company status provides equity upside potential and regulatory pathway visibility
Focused pipeline allows deep technical expertise development in a specialized domain

Watch Out For

Severe cash burn ($12.2M loss in FY2025 on only $574K revenue in FY2024) with just $5M cash remaining—liquidity crisis likely within 12-24 months
Zero active job openings and no published hiring activity indicate team contraction, not growth
Minimal clinical validation (3 trials, no defined phase designation) and no revenue-generating products mean compensation and job security remain highly uncertain

Generated by Claude from Aethlon Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

NCT04595903Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® Device

N/A

NCT04453046Hemopurifier Plus Pembrolizumab in Head and Neck Cancer

N/A